You pointed out that there certainly can be cases where meslamines could help chrohns patients.But they're not really Crohn's patients are they? At the least it's borderline Crohn's without all of the features of normal Crohn's e.g. transmural inflammation.
Single payer seems to have its benefits and drawbacks.I got onto Remicade, Humira and Entyvio pretty quickly. I'm not saying everyone on the NHS is that lucky but not everyone in America is that lucky either.
The waiting times are vastly exaggerated by those who have vested interests in downplaying national healthcare. But even if you do have to wait longer in some cases, for me I'd rather do that than pay $10K a year for decent quality healthcare.
It also can't be a coincidence that almost all of the medications (and even the surgical procedures) used by members here weren't developed in countries with a nationalized health care system. That has to mean something.I don't know about
that. Europe and Japan has come out with treatments for IBD that seem to have been entirely ignored by America, e.g. adacolumn apheresis. Thomas Borody is busy plugging away on his anti-MAP pill in Australia and prof. John Hunter on his anti-MAP vaccine in the UK. And a surgery that I am keenly interested in has originated in Europe:
ostomycure.com/Reckon we'd manage without America's input tbh.
PS: How did I forget about
the j-pouch? My first hospital, St. Mark's, invented that!